Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27458231
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Exploiting Interkingdom Interactions for Development of Small-Molecule Inhibitors
of Candida albicans Biofilm Formation
#MMPMID27458231
Reen FJ
; Phelan JP
; Gallagher L
; Woods DF
; Shanahan RM
; Cano R
; Ó Muimhneacháin E
; McGlacken GP
; O'Gara F
Antimicrob Agents Chemother
2016[Oct]; 60
(10
): 5894-905
PMID27458231
show ga
A rapid decline in the development of new antimicrobial therapeutics has
coincided with the emergence of new and more aggressive multidrug-resistant
pathogens. Pathogens are protected from antibiotic activity by their ability to
enter an aggregative biofilm state. Therefore, disrupting this process in
pathogens is a key strategy for the development of next-generation
antimicrobials. Here, we present a suite of compounds, based on the Pseudomonas
aeruginosa 2-heptyl-4(1H)-quinolone (HHQ) core quinolone interkingdom signal
structure, that exhibit noncytotoxic antibiofilm activity toward the fungal
pathogen Candida albicans In addition to providing new insights into what is a
clinically important bacterium-fungus interaction, the capacity to modularize the
functionality of the quinolone signals is an important advance in harnessing the
therapeutic potential of signaling molecules in general. This provides a platform
for the development of potent next-generation small-molecule therapeutics
targeting clinically relevant fungal pathogens.
free
free
free
